A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
NCT01415102 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2011-08-15
Summary
The purpose of this study in healthy people is to evaluate safety, toleration and time course of plasma concentration of single inhaled doses of PF-05212372.
Conditions
- Phase 1
- Single Dose
- Safety
- Toleration
- Pharmacokinetics
Interventions
- DRUG
-
PF-05212372
Inhaled. Dose Level 1: 50 ug
- DRUG
-
PF-05212372
Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
PF-05212372
Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
PF-05212372
Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
Inhaled
- DRUG
-
PF-05212372
Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
PF-05212372
Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
PF-05212372
Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
- DRUG
-
Inhaled
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- RANDOMIZED
- Purpose
- BASIC_SCIENCE
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-09-30
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- Belgium
Study Locations
More Related Trials
-
A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162
NCT01691274 ·Status: COMPLETED ·Phase: PHASE1
-
First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects
NCT03309241 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers
NCT00992342 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers
NCT00797342 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512
NCT03146065 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose, Dose Escalation Healthy Volunteers Study Of PF-05105679
NCT01393652 ·Status: COMPLETED ·Phase: PHASE1
-
STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS
NCT04756531 ·Status: COMPLETED ·Phase: PHASE1
-
A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
NCT05654181 ·Status: COMPLETED ·Phase: PHASE1
-
Dose Escalation Study of PF-06741086 In Healthy Subjects
NCT02531815 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People
NCT05411588 ·Status: COMPLETED ·Phase: PHASE1
-
Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects
NCT01012310 ·Status: COMPLETED ·Phase: PHASE1
-
Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults
NCT01753791 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
NCT01238679 ·Status: TERMINATED ·Phase: PHASE1
-
A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals
NCT01089738 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants
NCT04323124 ·Status: TERMINATED ·Phase: PHASE1
-
First-in-Human Study of PF-04958242 in Healthy Volunteers
NCT01159483 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study of PF-05230907 in Healthy Japanese Subjects
NCT02537002 ·Status: COMPLETED ·Phase: PHASE1
-
A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects
NCT02316756 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
NCT05907395 ·Status: COMPLETED ·Phase: PHASE1
-
Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571
NCT03092232 ·Status: COMPLETED ·Phase: PHASE1
-
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617 ·Status: COMPLETED ·Phase: PHASE1
-
A First-In-Human Study of the Study Medicine, Called PF-07291177, in Healthy Adult Participants
NCT05434091 ·Status: WITHDRAWN ·Phase: PHASE1
-
Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants
NCT04388878 ·Status: COMPLETED ·Phase: PHASE1
-
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
NCT01140672 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)
NCT01934738 ·Status: COMPLETED ·Phase: PHASE1